source
- BioNTech's mRNA cancer therapy fails to improve progression-free survival in head-neck cancer trialBioNTech reported that its experimental mRNA cancer immunotherapy, BNT 113, combined with Keytruda, did not meet the primary endpoint of progression-free survival in an interim analysis of a late-s…
- BioNTech's head and neck cancer vaccine fails to meet first primary endpoint in pivotal trialBioNTech reported that its experimental mRNA vaccine targeting head and neck cancer did not achieve one of the two primary goals in a pivotal study. The trial was designed to evaluate the vaccine’…